Clinical Obesity最新文献

Background and aims: Weight recidivism following sleeve gastrectomy (SG) is common. Adjuvant treatments include new glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptor agonists (GLP1/GIP-RA) or revisional endoscopic sleeve gastroplasty (R-ESG). We here compare the outcomes of these treatments.

Methods: A retrospective study of patients ≥18 years with prior SG treated with semaglutide, tirzepatide or R-ESG for weight recidivism between January 2019 and 2023 at large academic centre. Primary outcomes were total body weight loss (TBWL) and adverse events (AEs). Secondary outcomes were changes in metabolic parameters. Tertiary outcome was to compare GLP1/GIP-RA outcomes in SG patients to matched patients with intact stomach.

Results: Our study included 68 (prior SG + GLP1/GIP-RA) and 22 (prior SG + R-ESG). R-ESG offered higher TBWL% than GLP1/GIP-RA at 3 (11.2% vs. 4.3%, p < .001), 6 (13.5% vs. 6.8%, p < .001) and 12 months (13.4% vs. 9.2%, p = .07) with no significant difference in AEs or change in metabolic parameters. On subgroup analysis, tirzepatide achieved similar 12-months TBWL% as R-ESG (13.2% vs. 13.4%, p = .9) and significantly more than semaglutide (13.2% vs. 8.1%, p = .04). Compared to patients with intact stomach (n = 87), GLP1/GIP-RA achieved significantly lower TBWL% in patients with prior SG at 3 (4.3% vs. 5.7%, p = .02), 6 (6.8% vs. 9.2%, p = .02) and 12 months (9.2% vs. 12.7%, p = .03). Medication refills were difficult in 41.3% of patients.

Conclusions: In a single-centre real-world experience study, R-ESG and tirzepatide appear to offer more weight loss than semaglutide in SG patients with weight recidivism although GLP1/GIP-RA were underdosed. GLP1/GIP-RA achieved higher weight loss in patients with intact stomach than those with prior SG.

While the association between ultra-processed food (UPF) consumption and chronic non-communicable diseases in adults is well-established, its relationship with serum markers of chronic diseases in children remains underexplored. This research investigates changes in serum markers in children with obesity during a trial aimed at reducing UPF consumption. The study is a prospective cohort, based on a parallel randomized controlled trial conducted between August 2018 and February 2020, with children aged 7-12 years. Over 6 months, children and their guardians attended monthly consultations and educational activities aimed at reducing UPF consumption. Body weight, height, and 24-h dietary recall were measured at all visits. Serum markers were collected at baseline and at the 2- and 5-month visit (during the intervention). Data from 95 children were analysed. Body mass index (BMI), UPF consumption in grams and energy, and percentage of UPF in grams showed a quadratic trend, initially decreasing, followed by an increase in the following months. Glucose, insulin, and HOMA-IR decreased throughout the study, but after adjustment for BMI, the associations no longer persisted, except for glucose levels, which decreased linearly by 2.25 mg/dL. Reducing UPF consumption may lower blood glucose levels in children with obesity, independent of BMI changes.

Background: Recurrent weight gain (RWG) is a major post-operative challenge among metabolic and bariatric surgery (MBS) patients. Binge eating behaviours (BEB) and food addiction (FA) have been identified as significant predictors of post-MBS RWG. However, limited research has investigated their independent associations with post-MBS RWG.

Methods: This cross-sectional study collected data via a self-reported questionnaire of post-MBS patient demographics and eating behaviours from a single-site academic obesity medicine program. The Binge Eating Scale and Yale Food Addiction Scale 2.0 collected data on BEB and FA exposure variables, respectively. ANOVA/chi-square tests determined bivariate associations with BEB and FA, while multivariable logistic regression models examined independent adjusted associations of BEB and FA with RWG% cut-offs.

Results: Of the 294 MBS patients (90.48% female, and 51.71% non-Hispanic white), 42.3% had BEB, 12.55% had severe FA, 7.36% moderate FA, and 7.36% mild FA. After adjustment, BEB was significantly associated with all magnitudes of post-MBS RWG, with the highest odds observed at 50% RWG [OR = 3.07; 95% CI: 1.45, 6.49; p = 0.003]. FA was not significantly associated with post-MBS RWG.

Conclusion: Results showed that BEB, but not FA, was associated with post-MBS RWG. MBS patient support teams should consider screening for BEB at post-MBS visits.

Pathologic values of body mass index (BMI), body weight, and waist circumference correlate with higher absolute and lower relative trunk strength. Whether waist-to-height ratio (WHtR) is appropriate for showing trunk strength differences in people with obesity and whether a continuous linear relationship exists between the increase in obesity and trunk strength is unknown. This retrospective cross-sectional study included 1174 subjects (1114 men and 60 women). Measured values included body weight, height, waist circumference, WHtR, BMI, and both absolute and body weight-adapted trunk flexor/extensor strength. Statistical analyses included t-tests, Welch tests, Pearson correlations, mixed-linear, and nonlinear regression analyses. Positive correlations with absolute trunk strength were found in subjects without obesity for all anthropometric parameters except WHtR. Weaker positive and partly negative correlation and linear regression coefficients were found in subjects with obesity. Nonlinear relationships were found between age, BMI, WHtR, and absolute respective body weight-adapted trunk strength. The relationship between obesity-defining measures/ indices and trunk strength is non-linear. Increasing BMI, waist circumference, or WHtR above cut-off values known from cardiovascular research is linked to a decrease or weaker increase in trunk strength. Body weight adaptation is recommended to avoid misinterpretation of apparently good absolute trunk strength values in people with obesity.

Specialist weight management services including bariatric surgery are commissioned within regions of England called Integrated Care Systems (ICSs) with eligibility and treatment guidelines determined as part of the National Institute for Health and Care Excellence (NICE) guidance. Reported variation in commissioning and bariatric surgery eligibility criteria has not been previously mapped. Freedom of Information (FOI) requests provide a tool, supported by legislation, to ask questions of public authorities including ICSs such that they must respond accurately. FOIs were sent to all 42 ICSs in England asking 4 questions aiming to establish whether there is variation in the commissioning of specialist weight management services and the eligibility criteria for bariatric surgery across England. Responses were presented descriptively and mapped across England. Responses were received from 41 out of 42 ICSs, with 34 reporting that they provide commissioned medical weight management programmes and 38 funding bariatric surgery. Thirteen reported using criteria that were not compliant with NICE guidance. A large area of the country centred around the East of England does not have a bariatric unit reducing access to care. There is significant geographical variation in the availability of both bariatric and specialist medical weight management services across England, with large portions of the country without local access to a service or no service at all. Where services are available, there is significant inconsistency in eligibility for bariatric surgery despite nationally available guidance.

The rate of weight reduction during obesity treatment declines over time and eventually reaches a weight plateau. We investigated factors associated with time to weight plateau (TTWP) in tirzepatide-treated participants with obesity or overweight in a post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 trials. Participants adherent to tirzepatide treatment and achieving ≥5% weight loss by primary endpoint (week 72 SURMOUNT-1; week 88 SURMOUNT-4) were included. Weight plateau was defined as a weight change <5% over a 12-week interval and all subsequent 12-week intervals. TTWP was time from randomization to the start of the first 12-week interval. Association between baseline characteristics and TTWP was assessed. Overall, 1438 participants in SURMOUNT-1 and 259 in SURMOUNT-4 were included. Across BMI categories (overweight, class I, II, and III), median TTWP in SURMOUNT-1 was 24.3, 26.0, 36.1, and 36.1 weeks, respectively (p <.05, class II and III vs. overweight). By week 72%, 90.2%, 88.9%, 87.6%, and 87.8% of participants in SURMOUNT-1 had reached a weight plateau across respective BMI categories. Higher doses of tirzepatide (10/15 mg), younger age, and female sex were more likely to reach a weight plateau later. Results in SURMOUNT-4 were similar. In this post-hoc analysis, most participants reached a weight plateau by week 72. Higher doses of tirzepatide, younger age, and female sex were associated with a longer TTWP. Further research into modifiers of weight reduction phases with tirzepatide may inform treatment decisions for its use in chronic weight management. Clinical Trial Registration: ClinicalTrials.gov, identifiers NCT04184622 (SURMOUNT-1) and NCT04660643 (SURMOUNT-4), available at http://www.clinicaltrials.gov/.

Background: Bariatric surgery is very effective in long-term weight management. The present study was undertaken to investigate the short-term effects of sleeve gastrectomy (SG) and of Roux-en-Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro-cecal transit time and (b) secretion of regulatory gut peptides and (c) their interrelationship.

Methods: Prospective single-centre study in which we assessed gastric emptying, oro-cecal transit time and gut peptide release in 28 severely obese individuals before and 2, respectively, 12 months after bariatric surgery (either SG or RYGB). Plasma PYY, GLP-1, ghrelin, insulin and glucose levels were measured fasting and after intake of a solid standard 459 kcal meal at each occasion. Gastric emptying was measured by 13 C octanoic acid breath testing, and oro-cecal transit time was measured by lactulose H₂ breath testing. Satiation was measured using VAS scores.

Results: After both RYGB and SG gastric emptying become significantly accelerated, and postprandial release of the distal gut peptides GLP-1 and PYY becomes significantly increased, pointing to ileal brake activation. Oro-cecal transit time becomes significantly accelerated after SG but not after RYGB. No significant correlations were observed between changes in distal gut peptide release, changes in GI motility and clinical parameters.

Conclusion: Both SG and RYGB resulted in significant weight loss and significantly affected GI motility and PYY and GLP-1 secretion. Subtle differences between both procedures were found in effect on oro-cecal transit time and patterns of peptide secretion.

The aim was to summarize the characteristics of exercise interventions based on the adherence of adults with obesity. Studies were identified through a systematic review of the literature conducted in databases in June 2022. The articles selected were from clinical trials involving adults with obesity. The total number of prescribed sessions and the mean or percentage of sessions attended by participants who completed the intervention were identified, along with details of the exercise prescription, including duration, attendance, and intensity control. A total of 21 studies were included in the synthesis. The adherence percentage ranged from 18% to 99% of the prescribed exercise sessions. Interventions that provided only guidance meetings for physical activities without supervising the training-allowing participants to choose the modality and loads-resulted in adherence to less than half of the prescribed sessions. The session duration and weekly attendance varied between 30-60 min and 2-3 times per week across the studies synthesized. These variables did not appear to significantly affect adherence percentages in this population. It was possible to conclude that supervised interventions, with combined training, which include moderate to high-intensity physical exercises and/or interval training and with some social support, resulted in greater adherence to sessions in adults with obesity.

Metabolic and bariatric surgeries (MBS), including Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy (SG), have proven effective in promoting long-term diabetes remission among patients with type-2 diabetes (T2D). In this multicentre retrospective cohort study, we investigated the effectiveness of RYGB and SG in achieving diabetes remission, specifically among patients with T2D and vascular complications, while accounting for similar baseline diabetes severity. Although various scores predict diabetes remission after bariatric surgery, they do not consider diabetes-related vascular complications, which can influence outcomes even in patients with similar baseline T2D severity. We collected preoperative data on microvascular (retinopathy, nephropathy, neuropathy) and macrovascular comorbidities (coronary artery disease, cerebrovascular accidents, peripheral artery disease) to compare the efficacy of RYGB and SG. Among 961 patients analysed, those with vascular complications showed higher remission rates with RYGB (OR: 1.97) compared to SG, despite similar baseline diabetes severity. Notably, RYGB patients with microvascular complications had a significant advantage in achieving T2D remission (OR: 2.95). However, no significant differences in remission were observed in patients with macrovascular complications. These findings suggest that RYGB may be more effective than SG in specific patient populations, particularly those with microvascular complications, emphasizing the need for personalized treatment strategies.

This study addresses the diagnostic challenges of identifying lymphoedema in patients with lipoedema using lymphoscintigraphy. Overdiagnosis of lymphoedema in this patient population is frequent and may result in reduced proposed surgical interventions. We retrospectively analyzed clinical data from patients followed for lipoedema, lymphoedema or lipolymphoedema and who underwent lymphoscintigraphy. All patients were assigned a clinical or lymphoscintigraphic diagnosis of lymphoedema and concordance between clinical and lymphoscintigraphic diagnosis was assessed. A modification of lymphoscintigraphic criteria interpretation was proposed to enhance the diagnosis specificity. We included 94 female patients (188 lower limbs). One hundred and thirty-seven limbs presented with signs of lipoedema (137/188; 72.9%) and 42 with clinical signs of lymphoedema (42/188; 22.3%). Overall, 125 limbs presented with a diagnosis of lymphoedema on lymphoscintigraphy (125/188; 66.5%). Using lymphoscintigraphy to diagnose lymphoedema in patients with lipoedema resulted in low specificity (38.3%). By adjusting the interpretation criteria of the lymphoscintigraphic anomalies, we could achieve a specificity of 80.85%, reducing the risk of overdiagnosing lymphoedema in patients with lipoedema. This study contributes to the ongoing efforts to optimize the assessment and management of patients with lipoedema and potential lymphatic involvement, by modifying the interpretation of lymphoscintigraphic criteria.